Merck says Keytruda improves survival before and after lung cancer surgery, awaits FDA decision next week
Merck announced Tuesday that patients with non-small cell lung cancer who received Keytruda before and after surgery lived longer than those …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
